Not just a woman's business! Understanding men and women's knowledge of HPV, the HPV vaccine, and HPV-associated cancers

Osazuwa-Peters, Nosayaba; Mohammed, Kahee A.; Tobo, Betelihem B.; Geneus, Christian J.; Schootman, Mario

doi:10.1016/j.ypmed.2017.03.014

Cited by 63 publications

(51 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the increase in incidence of HPV-associated cancers in men, interventions aimed at increasing HPV vaccine coverage should target both men and women. 34 The present study also showed racial/ethnic disparities in knowledge and awareness of HPV and HPV vaccine. Non-Hispanic Blacks had lower HPV awareness compared with non-Hispanic Whites.…”

Section: Discussionsupporting

confidence: 52%

Approaching a decade since HPV vaccine licensure: Racial and gender disparities in knowledge and awareness of HPV and HPV vaccine

Boakye

Tobo

Rojek

et al. 2017

Human Vaccines & Immunotherapeutics

Self Cite

110

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 52%

Approaching a decade since HPV vaccine licensure: Racial and gender disparities in knowledge and awareness of HPV and HPV vaccine

Boakye

Tobo

Rojek

et al. 2017

Human Vaccines & Immunotherapeutics

Self Cite

110

View full text Add to dashboard Cite

show abstract

“…Moreover, these studies have shown greater prevalence of infection in men, and HPV‐associated OSCC has been shown to be more common in men, both in the United States and other developed nations . HPV infections and associated cancers unfortunately suffer from a public misperception as a health issue unique to women; however, current HPV‐related cancer incidence trends underscore the opposite. In the United States, the incidence of HPV‐related OSCC in men has exceeded the incidence of cervical cancer, which is on the decline .…”

Section: Genital Oropharyngeal and Anal Hpv Infection In Menmentioning

confidence: 99%

Natural history of human papillomavirus and vaccinations in men: A literature review

Lieblong

Montgomery

et al. 2019

Health Science Reports

View full text Add to dashboard Cite

Background and aims Infection with high‐risk (HR) genotypes of the human papillomavirus (HPV) is necessary for and causative of almost all cervical cancers and their precursor condition, cervical intraepithelial neoplasia. These conditions have been sharply reduced by cervical cytology screening, and a further decrease is expected because of the recent introduction of prophylactic HPV vaccinations. While significant attention has been given to gynecologic HPV disease, men can be affected by HPV‐related cancers of the anus, penis, and oropharynx. This literature review aims to address disparities in HPV‐related disease in men, and certain HR male subpopulations, compared with women. Discussion Overall, immunocompetent men are far less likely than women to develop anogenital HPV‐related cancers, despite harboring HR HPV infections at anogenital sites. On the other hand, men who have sex with men and men living with human immunodeficiency virus infection are at considerably higher risk of HPV‐related disease. Historic rates of prophylactic HPV vaccination in males have trailed those of females due to numerous multilevel factors, although, in recent years, this sex gap in vaccination coverage has been closing. In the absence of routine HPV screening in males, therapeutic vaccinations have emerged as a potential treatment modality for preinvasive neoplasia and are in various phases of clinical testing. Conclusion Successful reductions in HPV disease morbidity at the population level must acknowledge and target HPV infections in men.

show abstract

“…The advanced stage at presentation among oropharyngeal tumors reported by Razzaghi et al emphasizes the urgency of these efforts. Without any effective preventive screening, primary prevention through HPV vaccination becomes critical . This is especially important, because nearly all HPV‐associated malignancies, including oropharyngeal cancers, are causally associated with HPV strains 16 and 18, which are covered by all existing HPV vaccines …”

mentioning

confidence: 99%

“…Although the oropharynx has become the most common HPV‐associated cancer site, the general understanding of the disease is in some ways limited compared with cervical cancer. Many clinicians still discuss HPV vaccines only in the context of cervical cancer, and many in the community, especially men, are still unaware of the association between HPV and oropharyngeal and other cancers . HPV vaccines are cancer‐preventive vaccines; and, hopefully, more physicians will continue to view every clinical encounter as an opportunity to discuss the vaccine with parents and eligible young adults to increase vaccine uptake .…”

mentioning

confidence: 99%

“…Without any effective preventive screening, primary prevention through HPV vaccination becomes critical. 17 This is especially important, because nearly all HPV-associated malignancies, including oropharyngeal cancers, are causally associated with HPV strains 16 and 18, which are covered by all existing HPV vaccines. 18,19 Although Razzaghi et al have filled some the gaps in our knowledge about HPV-associated cancer survivorship, questions remain that need to be addressed in future studies.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Survival of human papillomavirus‐associated cancers: Filling in the gaps

Osazuwa-Peters

Simpson

Boakye

et al. 2017

Cancer

Self Cite

View full text Add to dashboard Cite

Nearly 80 million individuals are currently infected with human papillomavirus (HPV) in the United States, making it the most common sexually transmitted infection. 1 The oncogenic strains of HPV are associated with virtually all cases of cervical cancer (including cancer in situ), 91% of anal cancer, 75% of vaginal cancer, 70% of oropharyngeal cancer, 69% of vulvar cancer, and 63% of penile cancer.2 In the last decade, it has been demonstrated that several rectal cancers could be associated with HPV because of the proximity of the anus and the rectum.3 Together, these HPV-associated cancers cost 7.5 million years of potential life lost and $3.7 billion in lost productivity. 4 Currently, there are an estimated 38,793 new cases of HPV-associated cancers in the United States, 5 which comprises approximately 2.3% of all new cancer cases in the United States.6 These cancers also contribute about 9% to the cancer mortality burden. 6 These statistics are troubling, given that most of these malignancies are preventable.5 Also concerning is the finding that the survival of patients with HPV-associated tumors varies greatly between demographic groups. These disparities are among the focus of the Healthy People 2020 initiative, 7 but mitigation efforts first require characterization of the disparities. In this issue of Cancer, the study by Razzaghi and colleagues 8 provides up-to-date data quantifying the problem of HPV-associated cancer survival. Several studies have described incidence trends of most HPV-associated cancers as well as preventive strategies. However, the literature on HPV-associated cancer survivorship have been overwhelmingly dominated by studies focusing on either cervical or oropharyngeal cancers. Thus, this novel effort by Razzaghi et al has filled a major gap in knowledge about the survival of patients with HPV-associated cancers. The authors describe how survival of cervical and oropharyngeal cancers compare with the other less studied, rarer HPV-associated cancers, including anal, vulvar, vaginal, and rectal cancers. They also highlight racial disparities in survivorship across HPV-associated cancers. In their study sample of almost one-quarter of a million diagnosed HPV-associated cancer cases across a decade (2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011), Razzaghi and colleagues observed survival rates as low as 47% for penile cancer and as high as 66% for vulvar cancer.8 They report that blacks consistently had lower survival rates than whites independent of which HPV-associated cancer was considered. In the context of health inequities and disparities, this finding of worse survival outcomes for blacks versus whites merits further discussion.Previous studies have attempted to describe differences in tumors based on race/ethnicity and have suggested biology as a potential basis for the survival differences observed in patients with cancer. However, there has been overwhelming evidence that the issues affecting cancer survivors are usually related to disease stage at presentat...

show abstract

Not just a woman's business! Understanding men and women's knowledge of HPV, the HPV vaccine, and HPV-associated cancers

Cited by 63 publications

References 42 publications

Approaching a decade since HPV vaccine licensure: Racial and gender disparities in knowledge and awareness of HPV and HPV vaccine

Approaching a decade since HPV vaccine licensure: Racial and gender disparities in knowledge and awareness of HPV and HPV vaccine

Natural history of human papillomavirus and vaccinations in men: A literature review

Survival of human papillomavirus‐associated cancers: Filling in the gaps

Contact Info

Product

Resources

About